The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance amid an ...

Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...

Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...

The latest health news includes China allowing foreign-owned hospitals in major cities, and the inclusion of AstraZeneca's ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a brand-name solution for intravenous infusion prescribed for certain cancers. Enhertu has no known interactions with alcohol, drugs, or supplements.